Background Pulmonary fibrosis is characterized by lung parenchymal destruction and can
increase morbidity and mortality. Pulmonary fibrosis commonly occurs following …

In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the …

After decades of research, two therapies for chronic fibrotic lung disease are now approved
by the FDA, with dozens more anti-fibrotic therapies in the pipeline. A great deal of …

The pandemic of coronavirus disease 2019 (COVID-19), caused by a novel severe acute
respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has caused an enormous …

Abstract Background Coronavirus disease 2019 (COVID-19) patients can develop
pulmonary fibrosis (PF), which is associated with impaired outcome. We assessed specific …

Abstract Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome
coronavirus 2 rapidly spread across the globe causing over 6 million deaths and major …

Abstract Coronavirus disease 2019 (COVID-19) has become a major health burden
worldwide, with over 450 million confirmed cases and 6 million deaths. Although the acute …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected hundreds of
millions of people worldwide, resulting in longterm complications for many. The multiorgan …

Introduction Outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection in patients with pre-existing idiopathic pulmonary fibrosis (IPF) remain …

Although pulmonary fibrosis can occur in the absence of a clear‐cut inciting agent, and
without a clinically clear initial acute inflammatory phase, it is more commonly associated …